Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 6/20 | 0.71 |
| ▸ | NTRK2 | Q16620 | 6/20 | 0.69 |
| ▸ | RAF1 | P04049 | 2/20 | 0.69 |
| ▸ | AURKA | O14965 | 1/20 | 0.69 |
| ▸ | SRC | P12931 | 1/20 | 0.69 |
| ▸ | FLT3 | P36888 | 6/20 | 0.60 |
| ▸ | FLT4 | P35916 | 4/20 | 0.60 |
| ▸ | KDR | P35968 | 4/20 | 0.60 |
| ▸ | KIT | P10721 | 2/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.54 |
| ▸ | CSF1R | P07333 | 3/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4002779 | 1.00 | NTRK1 (0.71) | NTRK1NTRK2RAF1AURKASRC | |
| SCHEMBL396703 | 0.96 | NTRK1 (0.76) | NTRK1NTRK2RAF1AURKASRC | |
| SCHEMBL396704 | 0.96 | NTRK1 (0.76) | NTRK1NTRK2RAF1AURKASRC | |
| SCHEMBL397409 | 0.95 | NTRK1 (0.69) | NTRK1NTRK2RAF1AURKASRC | |
| SCHEMBL397408 | 0.95 | NTRK1 (0.69) | NTRK1NTRK2RAF1AURKASRC | |
| SCHEMBL10091887 | 0.91 | NTRK2 (0.69) | NTRK1NTRK2RAF1AURKASRC | |
| SCHEMBL396340 | 0.91 | NTRK2 (0.69) | NTRK1NTRK2RAF1AURKASRC | |
| SCHEMBL10091867 | 0.90 | CSF1R (0.65) | NTRK1NTRK2RAF1AURKASRC | |
| SCHEMBL395674 | 0.90 | CSF1R (0.65) | NTRK1NTRK2RAF1AURKASRC | |
| SCHEMBL4553352 | 0.90 | NTRK1 (0.58) | NTRK1NTRK2RAF1AURKASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814545-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-06-10 | — | — | EP | claimed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | claimed |
| EP-1814545-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-08-08 | — | — | EP | claimed |
| WO-2006052936-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-18 | — | — | WO | claimed |
| EP-1814545-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-06-10 | — | — | EP | disclosed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| EP-1814545-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006052936-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, FRK, PTK2B | NTRK1 226/4885NTRK2 235/4885RAF1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.